| Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
|
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
| EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial |
|
eJHaem |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
|
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study |
|
European Journal of Haematology |
Aplastic Anemia |
| Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
|
Experimental Hematology |
Myelodysplastic Syndromes (MDS) |
| Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
|
Experimental Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
